• Target：
• NFKB1

• Fields：
• >>Antifolate resistance;>>MAPK signaling pathway;>>Ras signaling pathway;>>cAMP signaling pathway;>>Chemokine signaling pathway;>>NF-kappa B signaling pathway;>>HIF-1 signaling pathway;>>Sphingolipid signaling pathway;>>PI3K-Akt signaling pathway;>>Apoptosis;>>Longevity regulating pathway;>>Cellular senescence;>>Osteoclast differentiation;>>Neutrophil extracellular trap formation;>>Toll-like receptor signaling pathway;>>NOD-like receptor signaling pathway;>>RIG-I-like receptor signaling pathway;>>Cytosolic DNA-sensing pathway;>>C-type lectin receptor signaling pathway;>>IL-17 signaling pathway;>>Th1 and Th2 cell differentiation;>>Th17 cell differentiation;>>T cell receptor signaling pathway;>>B cell receptor signaling pathway;>>TNF signaling pathway;>>Neurotrophin signaling pathway;>>Prolactin signaling pathway;>>Adipocytokine signaling pathway;>>Relaxin signaling pathway;>>Insulin resistance;>>Non-alcoholic fatty liver disease;>>AGE-RAGE signaling pathway in diabetic complications;>>A

• Gene Name：
• NFKB1

• Protein Name：
• Nuclear factor NF-kappa-B p105 subunit

• Human Gene Id：
• 4790

• Human Swiss Prot No：
• P19838

• Mouse Gene Id：
• 18033

• Mouse Swiss Prot No：
• P25799

• Immunogen：
• Synthesized phospho-peptide around the phosphorylation site of human NFκB-p105/p50 (phospho Ser337)

• Specificity：
• Phospho-NFκB-p105/p50 (S337) Polyclonal Antibody detects endogenous levels of NFκB-p105/p50 protein only when phosphorylated at S337.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• WB 1:500 - 1:2000. IHC 1:100 - 1:300. ELISA: 1:40000.. IF 1:50-200

• Purification：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• NFKB1;Nuclear factor NF-kappa-B p105 subunit;DNA-binding factor KBF1;EBP-1;Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1

• Observed Band(KD)：
• 105kD,50kD

• Background：
• nuclear factor kappa B subunit 1(NFKB1) Homo sapiens This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. Alternative splicing results in multiple transcript variants encoding different isof

• Function：
• domain:Glycine-rich region (GRR) appears to be a critical element in the generation of p50.,domain:The C-terminus of p105 might be involved in cytoplasmic retention, inhibition of DNA-binding, and transcription activation.,function:NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Diff

• Subcellular Location：
• Nucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).

• Expression：
• Muscle,Rectum tumor,Uterus,

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs